Low-intensity Low-frequency Pulsed Ultrasound Ameliorates Sciatic Nerve Dysfunction in a Rat Model of Cisplatin-induced Peripheral Neuropathy
Affiliations
Chemotherapy-induced peripheral neuropathy is a neurological complication that frequently occurs during chemotherapeutic intervention, resulting in damaged myelin sheath, motor weakness and/or sensory impairment. This study aims to investigate the therapeutic efficiency of low-intensity pulsed low-frequency ultrasound on cisplatin-induced peripheral neuropathy. Rats were randomly divided into five experimental groups as control, cisplatin administration, 10 mg/kg melatonin treatment after cisplatin administration, 1 MHz frequency 0.5 W/cm pulsed ultrasound treatment after cisplatin administration and 1 MHz frequency 1.5 W/cm pulsed ultrasound treatment after cisplatin administration. Chemical neuropathy was induced by the injection of 3 mg/kg/week of cisplatin (i.p.) for 5 weeks. Afterwards, melatonin and pulsed ultrasound treatments were applied for 15 consecutive days. Cisplatin administration resulted in a decrease in nociceptive pain perception and nerve conduction velocities together with a decrease in myelin thickness and diameters of axons and myelinated fibers, indicating a dysfunction and degeneration in sciatic nerves. In addition, cisplatin administration led to a decrease, in superoxide dismutase activity, and an increase in malondialdehyde and IL-1β levels together with an increase in caspase-3 protein expression levels and a decrease in Bcl-2 and Parkin levels. The ultrasound treatments resulted in an increase in nociceptive pain perception and sciatic nerve conduction; led to a decrease in oxidative stress and inflammation, restored nerve degeneration and regulated apoptosis and mitophagy. Taken together, low-intensity pulsed low-frequency ultrasound was efficient in restoring the alterations attributable to cisplatin-induced peripheral neuropathy, and warrants further investigations.
Bagcaci S, Yilmaz R, Sahin N Turk J Phys Med Rehabil. 2023; 69(3):366-376.
PMID: 37674798 PMC: 10478536. DOI: 10.5606/tftrd.2023.12467.
Ahmed Y, Orfali R, Hamad D, Rateb M, Farouk H Pharmaceutics. 2022; 14(8).
PMID: 35893792 PMC: 9394333. DOI: 10.3390/pharmaceutics14081536.